National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary—Clinical characteristics and disease course of 44 patients with juvenile dermatomyositis

References

• Potain C. Morve chronique de forme anomale. Bull Soc Hop Paris 1875; 314
   Google Scholar
• Rider LG, Miller FW. New perspectives on the idiopathic inflammatory myopathies of childhood. Curr Opin Rheumatol 1994; 6: 575–582
   PubMedGoogle Scholar
• Rider LG, Miller FW. Idiopathic inflammatory muscle disease: Clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 37–54
   PubMedGoogle Scholar
• Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087–1095
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002; 4: 415–426
   PubMedGoogle Scholar
• Sontheimer RD. Dermatomyositis: An overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002; 20: 387–408
   PubMed Web of Science ®Google Scholar
• Sontheimer RD, Kovalchick P. Cutaneous manifestations of rheumatic diseases: Lupus erythematosus, dermatomyositis, scleroderma. Dermatol Nurs 1998; 10: 81–95
   PubMedGoogle Scholar
• Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 1999; 11: 475–482
   PubMedGoogle Scholar
• McCauliffe DP, Sontheimer RD. Dermatologic manifestations of rheumatic disorders. Prim Care 1993; 20: 925–941
   PubMedGoogle Scholar
• Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998; 39: 899–920
   PubMed Web of Science ®Google Scholar
• Spiera R, Kagen L. Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 1998; 10: 556–561
   PubMedGoogle Scholar
• Adams EM, Plotz PH. The treatment of myositis. How to approach resistant disease. Rheum Dis Clin North Am 1995; 21: 179–202
   PubMed Web of Science ®Google Scholar
• Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360–374
   PubMed Web of Science ®Google Scholar
• Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality. Rheumatology (Oxford) 2002; 41: 22–26
   PubMed Web of Science ®Google Scholar
• Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245–250
   PubMed Web of Science ®Google Scholar
• Ertekin C, Secil Y, Yuceyar N, Aydogdu I. Oropharyngeal dysphagia in polymyositis/dermatomyositis. Clin Neurol Neurosurg 2004; 107: 32–37
   PubMed Web of Science ®Google Scholar
• Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis–dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182–1185
   PubMed Web of Science ®Google Scholar
• Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63: 297–301
   PubMed Web of Science ®Google Scholar
• Laskin BL, Choyke P, Keenan GF, Miller FW, Rider LG. Novel gastrointestinal tract manifestations in juvenile dermatomyositis. J Pediatr 1999; 135: 371–374
   PubMedGoogle Scholar
• Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep 2005; 7: 99–105
   PubMedGoogle Scholar
• Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995; 122: 715–724
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002; 41: 7–13
   PubMed Web of Science ®Google Scholar
• Lundberg I, Chung Y. Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology (Oxford) 2000; 39: 7–17
   PubMed Web of Science ®Google Scholar
• Mosca M, Neri R, Pasero G, Bombardieri S. Treatment of the idiopathic inflammatory myopathies: A retrospective analysis of 63 Caucasian patients longitudinally followed at a single center. Clin Exp Rheumatol 2000; 18: 451–456
   PubMedGoogle Scholar
• Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 2003; 16: 569–575
   PubMed Web of Science ®Google Scholar
• Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 1143–1149
   PubMed Web of Science ®Google Scholar
• Reed AM, Lopez M. Juvenile dermatomyositis: Recognition and treatment. Paediatr Drugs 2002; 4: 315–321
   PubMedGoogle Scholar
• Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997; 23: 619–655
   PubMed Web of Science ®Google Scholar
• Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol 1996; 23: 1424–1427
   PubMed Web of Science ®Google Scholar
• Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: Efficacy and safety. J Rheumatol 2000; 27: 2498–2503
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 467–474
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology 1998; 51(6 Suppl 5)S37–S45
   Google Scholar
• Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies: Experience based on controlled clinical trials. Neurol Sci 2003; 24(Suppl 4)S256–S259
   PubMed Web of Science ®Google Scholar
• Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61: 37–41
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. The management of dermatomyositis: Current treatment options. Expert Opin Pharmacother 2004; 5: 1083–1099
   PubMed Web of Science ®Google Scholar
• Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19: 138–141
   PubMed Web of Science ®Google Scholar
• Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47: 505–511
   PubMed Web of Science ®Google Scholar
• Villalba L, Adams EM. Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol 1996; 8: 544–551
   PubMedGoogle Scholar
• Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 2003; 23: 199–206
   PubMedGoogle Scholar
• Zipitis CS, Baildam EM, Ramanan AV. Treatment approaches to juvenile dermatomyositis. Expert Opin Pharmacother 2004; 5: 1509–1515
   PubMed Web of Science ®Google Scholar
• Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): An alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44: 386–389
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971–982
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005; 52: 601–607
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: Long-term follow-up. Eur Neurol 2004; 52: 61–63
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations. Eur Neurol 2003; 50: 10–15
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 180–185
   PubMed Web of Science ®Google Scholar
• Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999; 92: 161–169
   PubMed Web of Science ®Google Scholar
• Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001; 144: 894–897
   PubMedGoogle Scholar
• Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: A study of composition and treatment. J Pediatr 2001; 138: 763–766
   PubMed Web of Science ®Google Scholar
• Oliveri MB, Palermo R, Mautalen C, Hubscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996; 23: 2152–2155
   PubMed Web of Science ®Google Scholar
• Palmieri GM, Sebes JI, Aelion JA, Moinuddin M, Ray MW, Wood GC, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum 1995; 38: 1646–1654
   PubMedGoogle Scholar
• Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol 2005; 15: 102–104
   PubMed Web of Science ®Google Scholar
• Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: A pilot study. J Dermatolog Treat 2004; 15: 35–39
   PubMedGoogle Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403–407
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–347
   PubMed Web of Science ®Google Scholar
• Phillips BA, Zilko P, Garlepp MJ, Mastaglia FL. Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 1998; 21: 1668–1672
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: Short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230–2237
   PubMed Web of Science ®Google Scholar
• Parodi A, Caproni M, Marzano AV, De Simone C, La Placa M, Quaglino P, et al. Dermatomyositis in 132 patients with different clinical subtypes: Cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm Venereol 2002; 82: 48–51
   PubMed Web of Science ®Google Scholar
• Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: Clinical characteristics of 79 children. J Rheumatol 1998; 25: 1198–1204
   PubMed Web of Science ®Google Scholar
• Peloro TM, Miller OF, 3rd, Hahn TF, Newman ED. Juvenile dermatomyositis: A retrospective review of a 30-year experience. J Am Acad Dermatol 2001; 45: 28–34
   PubMed Web of Science ®Google Scholar
• Shehata R, al-Mayouf S, al-Dalaan A, al-Mazaid A, al-Balaa S, Bahabri S. Juvenile dermatomyositis: Clinical profile and disease course in 25 patients. Clin Exp Rheumatol 1999; 17: 115–118
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002; 28: 833–857
   PubMed Web of Science ®Google Scholar
• Targoff IN, Miller FW, Medsger TA, Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9(6)527–535
   PubMedGoogle Scholar
• Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002; 28: 779–798
   PubMed Web of Science ®Google Scholar
• Pachman LM. Juvenile dermatomyositis: Immunogenetics, pathophysiology, and disease expression. Rheum Dis Clin North Am 2002; 28: 579–602
   PubMedGoogle Scholar
• Adams EM, Chow CK, Premkumar A, Plotz PH. The idiopathic inflammatory myopathies: Spectrum of MR imaging findings. Radiographics 1995; 15: 563–574
   PubMed Web of Science ®Google Scholar
• Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, et al. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994; 95: 166–172
   PubMed Web of Science ®Google Scholar
• Chan WP, Liu GC. MR imaging of primary skeletal muscle diseases in children. AJR Am J Roentgenol 2002; 179: 989–997
   PubMedGoogle Scholar
• Cleland JA, Venzke JW. Dermatomyositis: Evolution of a diagnosis. Phys Ther 2003; 83: 932–945
   PubMedGoogle Scholar
• Dalakas MC. The future prospects in the classification, diagnosis and therapies of inflammatory myopathies: A view to the future from the “bench-to-bedside”. J Neurol 2004; 251: 651–657
   PubMedGoogle Scholar
• Dion E, Cherin P, Payan C, Fournet JC, Papo T, Maisonobe T, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29: 1897–1906
   PubMed Web of Science ®Google Scholar
• Friedman JM, Pachman LM, Maryjowski ML, Radvany RM, Crowe WE, Hanson V, et al. Immunogenetic studies of juvenile dermatomyositis: HLA-DR antigen frequencies. Arthritis Rheum 1983; 26: 214–216
   PubMedGoogle Scholar
• Furuya T, Hakoda M, Higami K, Ueda H, Tsuchiya N, Tokunaga K, et al. Association of HLA class I and class II alleles with myositis in Japanese patients. J Rheumatol 1998; 25: 1109–1114
   PubMedGoogle Scholar
• Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, Miller FW, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum 2000; 43: 1866–1873
   PubMedGoogle Scholar
• Marie I, Cardon T, Hachulla E, Cotten A, Michon-Pasturel U, Hatron PY, et al. Magnetic resonance imaging in focal myositis. J Rheumatol 1998; 25(2)378–382
   PubMedGoogle Scholar
• Targoff IN. Laboratory manifestations of polymyositis/dermatomyositis. Clin Dermatol 1988; 6: 76–92
   PubMedGoogle Scholar
• Targoff IN. Diagnosis and treatment of polymyositis and dermatomyositis. Compr Ther 1990; 16: 16–24
   PubMedGoogle Scholar
• Targoff IN. Idiopathic inflammatory myopathy: Autoantibody update. Curr Rheumatol Rep 2002; 4: 434–441
   PubMedGoogle Scholar
• Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996; 23: 1794–1797
   PubMedGoogle Scholar
• Aleksza M, Szegedi A, Antal-Szalmas P, Irinyi B, Ponyi L, et al. Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis 2005, [Epub ahead of print]
   PubMedGoogle Scholar
• Reed AM, Mason T. Recent advances in juvenile dermatomyositis. Curr Rheumatol Rep 2005; 7: 94–98
   PubMedGoogle Scholar
• Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 541–549
   PubMed Web of Science ®Google Scholar
• Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14: 263–274
   PubMed Web of Science ®Google Scholar
• Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: A longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83: 35–42
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Epidemiology of polymyositis/dermatomyositis. Mt Sinai J Med 1988; 55: 447–452
   PubMedGoogle Scholar
• Hochberg MC, Lopez-Acuna D, Gittelsohn AM. Mortality from polymyositis and dermatomyositis in the United States, 1968–1978. Arthritis Rheum 1983; 26: 1465–1471
   PubMed Web of Science ®Google Scholar
• Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 2005; 44: 83–88
   PubMed Web of Science ®Google Scholar